Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.

Joseph A Puma,Lesan T Banko,Karen S Pieper,Terrence J Sacchi,J Conor O'Shea, Jean Pierre Dery,James E Tcheng

msra（2006）

引用 23|浏览7

暂无评分

摘要

Although eptifibatide treatment improved outcomes for all patients, preprocedural clinical characteristics can define a subgroup of patients who may derive greatest benefit from its use during coronary stent placement.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要